Ovarian epithelial cancer stage III – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:29:09 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ovarian epithelial cancer stage III – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness of Olaparib and Bevacizumab for Maintenance Treatment in Patients with HRD-Positive Ovarian Cancer https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-olaparib-and-bevacizumab-for-maintenance-treatment-in-patients-with-hrd-positive-ovarian-cancer/ Wed, 29 Apr 2026 14:24:07 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-olaparib-and-bevacizumab-for-maintenance-treatment-in-patients-with-hrd-positive-ovarian-cancer/ This clinical trial is focused on studying the effectiveness of a treatment for patients with advanced, high-grade epithelial ovarian cancer, including cancer of the fallopian tube or primary peritoneal cancer. The study involves patients whose tumors show a specific genetic defect in a DNA repair mechanism known as homologous recombination deficiency (HRD). The treatment being tested combines two medications: olaparib, which is a type of drug known as a PARP inhibitor, and bevacizumab, a monoclonal antibody. These medications are given as maintenance therapy, which means they are used to help keep the cancer from coming back after the initial treatment.

The purpose of the study is to confirm how well this combination works in patients who have already received a standard chemotherapy treatment that includes a platinum-based drug and bevacizumab. After completing this initial treatment, patients who show a complete or partial response and have HRD-positive tumors will start taking olaparib along with bevacizumab. The study will observe how patients respond to this maintenance therapy over time.

Participants in the trial will receive the treatment over a period of time, and their health will be monitored to see how the cancer responds and to check for any side effects. The study aims to provide more information about the effectiveness and safety of using olaparib and bevacizumab together in treating this type of cancer. The trial will also gather data on the characteristics of patients who benefit from this treatment approach.

]]>